A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 19 Sep 2019
Price :
$35 *
At a glance
- Drugs OMP 336B11 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 16 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2019 Planned End Date changed from 30 Jul 2019 to 1 Oct 2019.
- 26 Aug 2019 Planned primary completion date changed from 5 Jul 2019 to 1 Sep 2019.